BioBuzz interviewed Silvia Fossati, PhD, Associate Professor of Neural Sciences and Cardiovascular Sciences at the Lewis Katz School of Medicine at Temple University, and Elisa Canepa, PhD, Associate Scientist with the Alzheimer’s Center at Temple, about new research at the Katz School of Medicine which shows that in experiments carried out in mice, drugs known as carbonic anhydrase inhibitors (CAIs) promote the clearance of amyloid beta from blood vessels and glial cells, which control brain inflammatory processes. In doing so, CAIs not only reduce inflammation and restore cell function but also prevent cognitive impairment. The study took place in the lab of Dr. Fossati and is the first to test the FDA-approved CAIs acetazolamide and methazolamide in animals with cerebrovascular alterations mimicking those of cerebral amyloid angiopathy and Alzheimer’s disease in humans. The results appeared online in the journal Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH